New Publication: Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
Home
>
Science Hub
>
New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
April 11, 2024
Hartmut Koeppen et al. The Journal of Pathology
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
You might also be interested by
Brochures & Infographics
Improved whole transcriptome sequencing for challenging clinical samples: A streamlined alternative to targeted RNA-seq
June 15, 2026
More infoPosters
Advancing B-Cell Monitoring in B-Cell-Depleting Therapies for Autoimmune Disorders
June 8, 2026
More infoUncategorized
Accelerating spectral flow cytometry assay development for clinical trials with a flexible panel design
June 8, 2026
More info